Xinyao Zhao1, Qingqing Wen2, Weiqiang Dou2, and Junying Wang3
1Department of Radiology, Yantaishan Hospital, Yantai , Shandong Province, China, 2GE Healthcare, MR Research China, Beijing, China, 3Shandong Province Qianfoshan Hospital, Jinan, Shandong Province, China
Synopsis
Keywords: Liver, Diffusion/other diffusion imaging techniques, IVIM
The accurate evaluation of tumor response after Transarterial
Chemoembolization (TACE) treatment is important for tumor prognosis and
subsequent treatment. In this study, we comprehensively investigated the
feasibility of IVIM parameters in the TACE treatment area, peritumoral area,
and hepatic parenchymal to predict tumor recurrence in hepatocellular carcinoma
patients after TACE treatment. ADC and D of TACE-treated area, and D of the peritumoral
area can predict the intralesional and peritumoral
recurrence after TACE treatment with high accuracy, indicating that IVIM might
be a useful tool in predicting the therapeutic response and the peritumoral
invasion.
Introduction
Transarterial Chemoembolization (TACE) is widely
used for the treatment of hepatocellular carcinoma (HCC) patients who were not
suitable for radical treatments. (1) However, there is still a high incidence of local
tumor recurrence following treatment with TACE. (2) The accurate detection of intralesional and
peritumoral recurrence plays a crucial role in the follow-up process. (3) Previous
studies have reported that IVIM might be a useful tool for predicting the
response of HCC to TACE. (4,5) However, these studies mainly focused on the prediction effect of IVIM
parameters in the TACE-treated area, and the results were not consistent.
Limited studies have comprehensively compared the prediction power of IVIM
parameters in the TACE-treated area, peritumoral area, and the parenchyma of
the liver in detecting the intralesional and peritumoral recurrence after TACE
treatment. This study aimed to systematically evaluate the clinical feasibility
of IVIM-derived metrics in predicting the therapeutic response of HCC to TACE,
in order to facilitate the formulation of more aggressive therapeutic
strategies. Methods
This prospective study involved 47 HCC patients who
were previously treated with TACE between January 2018 to December 2021. The MR imaging was performed on a 3.0 T system
(Discovery MR750, GE Healthcare, MI, United States) with an eight-channel
abdomen coil. Before the MR examination, each patient was instructed to fast
for six to eight hours. IVIM-DWI was performed in an axial plane using a respiratory-gated
spin-echo echo-planar imaging sequence (SE-EPI). 10 different b values between
0 and 1000 s/mm2 (25, 50, 75, 100, 200, 400, 600, 700, 800, and
1000) were used. The other parameters of IVIM-DWI were as follows: repetition
time ranged from 4000 to 20000, echo time 52.9ms, bandwidth 250kHz/pixel, acquisition matrix 128×130, field of view 360mm×288mm,
slice thickness 8mm, and slice gap 2mm.
In the follow-up, according to
the modified Response Evaluation Criteria in Solid Tumors (mRECIST) (6), the
patients were divided into two groups – progressive and non-progressive groups.
ADC and IVIM-derived parameters (D, D*, f) were calculated on workstation 4.6 (GE Healthcare, USA). The regions of interests
(ROIs) were manually drawn on the original images (b=0) of the IVIM, including
ROI of the tumor solid area, ROI of the peritumoral area (distance<2 cm to
the tumor boundary), and ROI of the liver parenchyma (distance>5
cm from the tumor boundary). Then the four parameter values in the three
ROIs can be obtained. In addition, considering the inter-subject variation and
individual differences, the parameters of the peritumoral zone were normalized
by those of the non-tumor liver parenchyma, e.g., ADCstd=
ADCpt/ADClp, ADCpt and ADClp
represented the mean ADC values in the peritumoral and liver parenchyma.
The statistical analyses were conducted using SPSS software (IBM Corp.,
Armonk, NY, USA) and MedCalc software (v. 19.2.0 for Windows, Mariakerke,
Belgium). Using an independent sample t-test, IVIM
metrics were compared in the non-progressing groups and the progression groups.
Receiver operating characteristic (ROC) curves were used to evaluate the
ability of ADC, D, D*, and f to distinguish between the progressive and
non-progressive groups. For all statistical tests, P<0.05 was considered to
be statistically significant. Results
Table 1 and Fig. 1 show the mean values of ADC, D,
D*, and f in different ROIs and the corresponding t-test results between the progressive and non-progressive groups. Compared
to the progressive group, the non-progressive group showed greater
values of ADCtace and Dtace in the TACE-treated areas (P<0.05).
Similarly, there were significant differences between Dpt in the
peritumoral area and normalized parameter Dstd in the progressive
and non-progressive groups. As shown in Table 2, the AUC values of ADCtace,
Dtace, Dpt, and Dstd were 0.76, 0.71, 0.73,
and 0.77, respectively. Discussion
It was found that ADCtace, Dtace, Dpt,
and Dstd showed statistically significant differences between the
non-progressing groups and progressing groups (P<0.05). In addition, Dstd
in the peritumoral area showed a high predictive power (AUC = 0.77) in
predicting tumor response after TACE treatment, indicating that Dstd
may be useful for predicting the cellular invasion of the peritumoral liver zone. Ghadery et al. (5) and Fei Jia et al. (4) reported that the D value of the tumor region in
the non-progressive group was higher than that in the progressive group, which
was consistent with this study. When the tumor recurred, the cell density and
the nuclear-to-cytoplasmic ratio would increase, (7,8)resulting in limited diffusion of water, which
leads to the decrease of ADC and D values. There were no significant
differences in the Dlp*, Dlp, and flp of the
hepatic parenchyma between the two groups, suggesting that TACE seemed not to
have a significant effect on the normal liver parenchyma.Conclusion
This
study showed that ADCtace
and Dtace in the TACE-treated
area, Dpt and normalized parameter Dstd in the
peritumoral tissues can predict the therapeutic response of TACE with relatively high accuracy,
indicating that IVIM-derived
parameters may be helpful to evaluate HCC response to TACE, and sensitive
for monitoring perilesional tumor recurrence.Acknowledgements
No acknowledgement found.References
1. Lencioni R, de Baere T, Soulen MC,
Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for
hepatocellular carcinoma: A systematic review of efficacy and safety data.
Hepatology 2016;64(1):106-116.
2. Rou WS, Lee BS,
Moon HS, Lee ES, Kim SH, Lee HYJWJoGW. Risk factors and therapeutic results of
early local recurrence after transcatheter arterial chemoembolization.
2014;20(22):6995.
3. Takayasu K, Arii
S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M, Liver Cancer Study Group
of J. Overall survival after transarterial lipiodol infusion chemotherapy with
or without embolization for unresectable hepatocellular carcinoma: propensity
score analysis. AJR Am J Roentgenol 2010;194(3):830-837.
4. Jia F, Wu B, Yan
R, Li L, Wang K, Han DJJoMRI. Prediction Model for Intermediate‐Stage
Hepatocellular Carcinoma Response to Transarterial Chemoembolization.
2020;52(6):1657-1667.
5. Ghadery AH, Yazdi
NA, Bagheri H, Kazerooni AF, Salahshour F, Javidi SS, Saeedi S, Rad HS,
Shekarchi BJEJoR, Medicine N. Prediction of hepatocellular carcinoma response
to transarterial chemoembolization with intravoxel incoherent motion
diffusion-weighted imaging. 2022;53(1):1-8.
6. Lencioni R, Llovet
JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin
Liver Dis 2010;30(1):52-60.
7. Jia F, Wu B, Yan
R, Li L, Wang K, Han D. Prediction Model for Intermediate-Stage Hepatocellular
Carcinoma Response to Transarterial Chemoembolization. J Magn Reson Imaging
2020;52(6):1657-1667.
8. Zhang Y, Kuang S,
Shan Q, Rong D, Zhang Z, Yang H, Wu J, Chen J, He B, Deng Y, Roberts N, Shen J,
Venkatesh SK, Wang J. Can IVIM help predict HCC recurrence after hepatectomy?
Eur Radiol 2019;29(11):5791-5803.